North America Vascular Graft Market

North America Vascular Graft Market Analysis

The North America Vascular Graft Market size is estimated at USD 1.08 billion in 2025, and is expected to reach USD 1.30 billion by 2030, at a CAGR of 3.81% during the forecast period (2025-2030).

Cardiovascular disorders are becoming more prevalent, and advancements in scaffold materials and vascular graft designs are driving market growth. These innovations are accelerating the adoption of vascular grafts among healthcare providers, as they address critical clinical needs such as improved biocompatibility, reduced risk of complications, and enhanced durability. Additionally, the increasing focus on minimally invasive procedures and the growing demand for effective treatment options are further supporting the widespread adoption of vascular grafts in the North American healthcare sector. Medical professionals commonly use vascular prostheses (grafts) for various purposes, including hemodialysis blood access, trauma and aneurysm repair, and cardiovascular reconstruction.

For instance, according to the Thrombosis Canada February 2023 update, around 45,000 patients were diagnosed with deep vein thrombosis (DVT) annually in Canada, equating to an incidence rate of roughly 1-2 cases for every 1,000 individuals. Consequently, a standard Canadian family practice witnesses 2-4 DVT cases each year. This growing prevalence of DVT highlights the increasing need for vascular graft adoption in the healthcare sector, as these grafts play a critical role in managing and treating such conditions effectively.

Furthermore, an increase in the utilization and adoption of different types of vascular grafts for traumatic vascular injuries further promotes market growth in the region over the forecast period. For instance, as per the article published in September 2024 in the American Surgeon Journal, researchers from the United States assessed the adoption of ipsilateral versus contralateral vein grafts in patients with traumatic extremity vascular injuries, focusing on their utilization in clinical practices and the decision-making process for vascular graft selection. As a result of these comparative studies on vascular grafts, researchers find them increasingly appealing, leading to the development of more advanced products.

Moreover, a surge in product approvals and launches of innovative vascular grafts in North America is propelling the market growth during the forecast period. For instance, in June 2023, Endologix LLC, received the United States Food and Drug Administration (FDA) approval for the DETOUR System to treat patients with complex peripheral arterial disease (PAD). Percutaneous Transmural Arterial Bypass (PTAB) with the DETOUR System treats complex PAD. As a result of these advanced product approvals, demand for sophisticated vascular grafts is expected to surge, driving the market growth during the forecast period.

Key players are ramping up strategic activities, and with cardiovascular diseases on the rise, the adoption of vascular grafts is expected to grow substantially as healthcare providers increasingly integrate these solutions into treatment protocols. This trend is anticipated to drive notable market growth in the coming years. Yet, challenges such as unfavorable reimbursement scenarios and the looming threat of graft failures could temper this growth in North America.

North America Vascular Graft Market Trends

Kidney Failure Segment is Expected to Witness a Positive Growth Over the Forecast Period

Due to the rising prevalence of kidney diseases and the growing adoption of vascular grafts in treatments, the kidney failure segment is poised to capture a significant share of the market. The adoption of vascular grafts has been driven by their critical role in facilitating effective blood flow during kidney transplants, ensuring improved patient outcomes, and supporting the overall success of the procedure. While kidney transplants serve as a primary treatment for kidney failure, the procedure heavily relies on the use of vascular grafts.

Rising kidney disease prevalence in North America is driving the demand for vascular grafts. For example, according to the Ontario Statistics 2024 statistics published by the Kidney Foundation of Canada, 12,284 Ontarians with advanced chronic kidney disease required dialysis in 2024. As per the same source, more than 9,300 Ontarians were living with a functioning kidney transplant in the state. As these cases escalate, the likelihood of kidney failure and subsequent transplants increases, subsequently boosting the demand for vascular grafts and propelling segment growth in the coming years.

Moreover, research studies emphasizing protocols and guidelines for treating chronic kidney diseases bolster the adoption of vascular grafts. These studies provide critical insights that drive healthcare providers and institutions to integrate vascular grafts into treatment plans, ensuring compliance with established medical standards and improving patient outcomes. For instance, as per the article published by the researchers in Mexico in July 2023 in the Frontiers in Nephrology journal, the researchers unanimously endorse prioritizing native vessels for vascular access (VA) in Mexico. This is followed by the adoption of arteriovenous fistulas (AVFs) using vascular grafts, which are increasingly recognized for their potential to enhance patient outcomes and address specific clinical needs. Long-term catheters are reserved as the last option. Hence, owing to the emergence of such protocols further accentuates the segment growth over the forecast period.

Given the surge in kidney disease cases, the uptick in kidney transplants, and the notable emphasis on vascular grafts in related studies, the segment in focus is poised for substantial growth in the coming years.

United States is Expected to Witness Healthy Growth in the Market Over the Forecast Period

Robust healthcare infrastructure, rising cardiovascular disease rates, a concentration of major industry players, and widespread adoption of vascular grafts in surgeries are propelling the United States market. For instance, an October 2024 report from the Centers for Disease Control and Prevention highlighted that roughly 800,000 Americans experience a heart attack annually, with 600,000 being their first. This significant prevalence of first-time heart attacks is poised to boost the demand for vascular grafts in the United States, as healthcare providers increasingly adopt these devices to improve surgical outcomes and address the growing burden of cardiovascular conditions. This trend is expected to drive market expansion in the coming years.

Furthermore, research studies increasingly highlight the benefits of vascular grafts for treating chronic diseases, likely fueling market growth. For example, a January 2023 article in the Biofabrication journal by United States researchers revealed that the genipin-crosslinked DAM graft boasts an enhanced integrated structure, extended stability, optimal mechanical properties, and superior biocompatibility. Such advancements in research are expected to drive the adoption of advanced vascular grafts among healthcare providers, as these innovations address critical clinical needs and improve patient outcomes. This growing adoption is anticipated to significantly contribute to market expansion.

Given the surge in cardiovascular diseases and the mounting research underscoring the significance of advanced vascular grafts, the United States is set to experience notable growth in the coming years.

North America Vascular Graft Industry Overview

The North America vascular grafts market is semi-consolidated due to the presence of a few companies operating globally and regionally. The key players are engaged in various strategic activities such as product launches, study enrollments, partnerships, and collaborations to increase their product availability across the region. A few of the major companies in the market are Abbott Laboratories, B. Braun SE, Becton, Dickinson and Company, Cardinal Health and Cook Group (Cook Medical) among others.

North America Vascular Graft Market Leaders

North America Vascular Graft Market News

• July 2024: FuzeHub awarded a Manufacturing Grant to Anova Biomedical in collaboration with Cornell University. The grant will support the scaling of production for innovative materials and vascular grafts, facilitating broader adoption of these advanced vascular grafts in medical applications by addressing manufacturing scalability and enhancing accessibility for healthcare providers.
• March 2024: Peca Labs secured CE Mark for its exGraft family of vascular grafts. Developed on Peca Labs' proprietary polymer processing platform, the exGraft is a synthetic vascular graft designed for permanent expansion. exGraft vascular grafts serve as vascular prostheses, replacing or bypassing diseased or injured vessels. Following the recent clearance, exGraft added instructions for postoperative expansion, allowing up to 140% expansion using oversized balloon catheters.